Ignite Creation Date:
2025-12-24 @ 9:11 PM
Ignite Modification Date:
2026-02-06 @ 12:39 PM
Study NCT ID:
NCT04531904
Status:
COMPLETED
Last Update Posted:
2024-01-26
First Post:
2020-08-26
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Prospective Evaluation to Characterize the Real-World Performance of the EMBOVAC Aspiration Catheter
Sponsor:
Cerenovus, Part of DePuy Synthes Products, Inc.
Organization:
Study Overview
Official Title:
Prospective Evaluation to Characterize the Real-World Performance of the EMBOVAC Aspiration Catheter for Neurothrombectomy: A Post-Market Clinical Follow-up Trial.
Status:
COMPLETED
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PERFECT
Brief Summary:
A post-market study evaluating the EMBOVAC Aspiration Catheter in acute ischemic stroke patients with confirmed intracranial large vessel occlusion.
Detailed Description:
The PERFECT Study is a prospective, multi-center, single arm, post-market clinical follow-up study.
The objective of this post-market clinical follow-up study is to assess the performance of the EMBOVAC Aspiration Catheter in the treatment of acute ischemic stroke in a real-world clinical setting.
The study will also report on clot characteristics and clinical outcomes.
The objective of this post-market clinical follow-up study is to assess the performance of the EMBOVAC Aspiration Catheter in the treatment of acute ischemic stroke in a real-world clinical setting.
The study will also report on clot characteristics and clinical outcomes.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: